{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:25:30Z","timestamp":1778678730063,"version":"3.51.4"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/wnf.0000000000000096","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T13:36:25Z","timestamp":1442064985000},"page":"177-182","source":"Crossref","is-referenced-by-count":36,"title":["Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders"],"prefix":"10.1097","volume":"38","author":[{"given":"Roberto","family":"Canitano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"8","key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification.","volume":"36","author":"Lecavalier","year":"2006","journal-title":"J Autism Dev Disord"},{"issue":"9","key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.ridd.2014.04.020","article-title":"Depression and mood disorders among persons with autism spectrum disorders.","volume":"35","author":"Matson","year":"2014","journal-title":"Res Dev Disabil"},{"issue":"11","key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1469-7610.2012.02600.x","article-title":"Severe mood problems in adolescents with autism spectrum disorder.","volume":"53","author":"Simonoff","year":"2012","journal-title":"J Child Psychol Psychiatry"},{"key":"R6-3-20210203","first-page":"405849","article-title":"Parent report of community psychiatric comorbid diagnoses in autism spectrum disorders.","volume":"2011","author":"Rosenberg","year":"2011","journal-title":"Autism Res Treat"},{"issue":"6","key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4088\/JCP.12m07392","article-title":"Examining the comorbidity of bipolar disorder and autism spectrum disorders: a large controlled analysis of phenotypic and familial correlates in a referred population of youth with bipolar I disorder with and without autism spectrum disorders.","volume":"74","author":"Joshi","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/DBP.0b013e318213f56c","article-title":"Characterization of depression in children with autism spectrum disorders.","volume":"32","author":"Magnuson","year":"2011","journal-title":"J Dev Behav Pediatr"},{"issue":"1","key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-859X-11-16","article-title":"Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges.","volume":"11","author":"Mazzone","year":"2012","journal-title":"Ann Gen Psychiatry"},{"issue":"3","key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s13311-012-0126-9","article-title":"Treatment for co-occurring attention deficithyperactivity disorder and autism spectrum disorder.","volume":"9","author":"Davis","year":"2012","journal-title":"Neurotherapeutics"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/epi.12399","article-title":"Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit.","volume":"54","author":"Fosi","year":"2013","journal-title":"Epilepsia"},{"issue":"7","key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/dmcn.12121","article-title":"The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies.","volume":"55","author":"Santos","year":"2013","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11920-014-0437-0","article-title":"An update on medication management of behavioral disorders in autism.","volume":"16","author":"Baribeau","year":"2014","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.rasd.2014.05.006","article-title":"Aggressive Behavior Problems in Children with Autism Spectrum Disorders: Prevalence and Correlates in a Large Clinical Sample.","volume":"8","author":"Hill","year":"2014","journal-title":"Res Autism Spectr Disord"},{"issue":"1","key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chc.2013.07.005","article-title":"Psychopharmacologic management of serious behavioral disturbance in ASD.","volume":"23","author":"Stigler","year":"2014","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"16","key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents.","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2011.0015","article-title":"Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.","volume":"21","author":"Maayan","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jad.2010.11.025","article-title":"Occurrence of affective disorders compared to other psychiatric disorders in children and adolescents with 22q11.2 deletion syndrome.","volume":"136","author":"Jolin","year":"2012","journal-title":"J Affect Disord"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/WCO.0b013e32835ee64f","article-title":"Autism and social cognition in epilepsy: implications for comprehensive epilepsy care.","volume":"26","author":"Tuchman","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fpubh.2013.00031","article-title":"A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.","volume":"1","author":"Frye","year":"2013","journal-title":"Front Public Health"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1203\/PDR.0b013e31819e7168","article-title":"The role of epilepsy and epileptiform EEGs in autism spectrum disorders.","volume":"65","author":"Spence","year":"2009","journal-title":"Pediatr Res"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s10803-013-1888-6","article-title":"Incidence and behavioral correlates of epileptiform abnormalities in autism spectrum disorders.","volume":"44","author":"Mulligan","year":"2014","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.4081\/ni.2010.e10","article-title":"Autism Spectrum Disorder: Correlation between aberrant behaviors, EEG abnormalities and seizures.","volume":"2","author":"Hartley-McAndrew","year":"2010","journal-title":"Neurol Int"},{"issue":"4","key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s10803-013-1952-2","article-title":"Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis.","volume":"44","author":"Hirota","year":"2014","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4088\/JCP.v62n07a05","article-title":"An open trial of divalproex sodium in autism spectrum disorders.","volume":"62","author":"Hollander","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder.","volume":"9","author":"Hollander","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/01.jcp.0000227703.72117.bc","article-title":"Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.","volume":"26","author":"Anagnostou","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo- controlled study of valproate for aggression in youth with pervasive developmental disorders.","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.jcp.0000219924.04058.99","article-title":"Much improved outcome with gabapentin-divalproex combination in adults with bipolar disorders and developmental disabilities.","volume":"26","author":"Hellings","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10803-012-1661-2","article-title":"Brief report: retrospective case series of oxcarbazepine for irritabilityagitation symptoms in autism spectrum disorder.","volume":"43","author":"Douglas","year":"2013","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"R32-3-20210203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004703-200208000-00006","article-title":"Levetiracetam in autistic children: an open-label study.","volume":"23","author":"Rugino","year":"2002","journal-title":"J Dev Behav Pediatr"},{"issue":"6","key":"R33-3-20210203","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"R34-3-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pediatrneurol.2012.04.002","article-title":"Levetiracetam-induced reversible autistic regression.","volume":"47","author":"Camacho","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"2","key":"R35-3-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial.","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"R36-3-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.braindev.2004.06.006","article-title":"Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders.","volume":"27","author":"Canitano","year":"2005","journal-title":"Brain Dev"},{"issue":"10","key":"R37-3-20210203","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.braindev.2006.05.004","article-title":"Topiramate in children with autistic spectrum disorders.","volume":"28","author":"Mazzone","year":"2006","journal-title":"Brain Dev"},{"issue":"7","key":"R38-3-20210203","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder.","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"R39-3-20210203","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/cap.2014.0019","article-title":"Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder.","volume":"24","author":"Siegel","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"R40-3-20210203","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10803-013-1963-z","article-title":"STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.","volume":"44","author":"Erickson","year":"2014","journal-title":"J Autism Dev Disord"},{"key":"R41-3-20210203","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1038\/tp.2012.124","article-title":"A randomised controlled trial of bumetanide in the treatment of autism in children.","volume":"2","author":"Lemonnier","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"11","key":"R42-3-20210203","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"6","key":"R44-3-20210203","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004714-198712000-00005","article-title":"Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology.","volume":"7","author":"Kerbeshian","year":"1987","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"R45-3-20210203","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00004583-198726060-00021","article-title":"Lithium responsive manic-like symptoms in two individuals with autism and mental retardation.","volume":"26","author":"Steingard","year":"1987","journal-title":"J Am Acad Child and Adolesc Psychiatry"},{"issue":"9","key":"R46-3-20210203","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.neubiorev.2012.07.005","article-title":"GABA system dysfunction in autism and related disorders: from synapse to symptoms.","volume":"36","author":"Coghlan","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"R47-3-20210203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17460441.2012.678828","article-title":"New directions in the treatment of autism spectrum disorders from animal model research.","volume":"7","author":"Chadman","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"R48-3-20210203","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/DHPS.S39595","article-title":"Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder.","volume":"10","author":"Frye","year":"2014","journal-title":"Drug Health care Patient Saf"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:10:18Z","timestamp":1620976218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201509000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000096","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}